Bayer (BUL:BAYN) - Aandelenkoers, Nieuws & Analyse

BAYN Overzicht aandelen

Bayer Aktiengesellschaft is wereldwijd actief als biowetenschappelijk bedrijf. Meer informatie

BAYN fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	1/6

Beloningen

Verhandeld tegen 83.7% onder onze schatting van de reële waarde

De winst zal naar verwachting met 55.74% per jaar groeien

De winst is de afgelopen 5 jaar met 25.6% per jaar gegroeid

Risicoanalyse

Aandelen zijn zeer illiquide

De schulden worden niet goed gedekt door de operationele kasstroom

Bayer Aktiengesellschaft Concurrenten

Tchaikapharma High Quality Medicines AD

BUL:THQM

лв1.6b

Sopharma AD

BUL:SFA

лв928.1m

Teva Pharmaceutical Industries

NYSE:TEVA

US$19.4b

Sandoz Group

SWX:SDZ

CHF 17.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bayer
Historische aandelenkoersen
Huidige aandelenkoers	€19.84
52 Week Hoogtepunt	€35.22
52 Week Laag	€19.15
Bèta	1
11 maand verandering	-26.65%
3 maanden verandering	n/a
1 Jaar Verandering	-38.32%
33 jaar verandering	-56.39%
5 jaar verandering	n/a
Verandering sinds IPO	-60.93%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BAYN	BG Pharmaceuticals	BG Markt
7D	-2.8%	3.6%	-0.5%
1Y	-38.3%	6.6%	10.1%

Rendement versus industrie: BAYN presteerde slechter dan de BG Pharmaceuticals -sector, die het afgelopen jaar een rendement van 6.6 % opleverde.

Rendement versus markt: BAYN presteerde slechter dan BG Market, dat het afgelopen jaar een rendement van 10.1 % opleverde.

Prijsvolatiliteit

Is BAYN's price volatile compared to industry and market?
BAYN volatility
BAYN Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.3%
Market Average Movement	4.0%
10% most volatile stocks in BG Market	7.6%
10% least volatile stocks in BG Market	2.6%

Stabiele aandelenkoers: De aandelenkoers van BAYN is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van BAYN in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1863	94,245	Bill Anderson	www.bayer.com

Bayer Aktiengesellschaft is wereldwijd actief als biowetenschappelijk bedrijf. Het is actief in de segmenten Farmaceutische Producten, Gezondheid van de consument en Gewasbescherming. Het segment Farmaceutische Producten biedt producten op recept, voornamelijk voor cardiologie en vrouwengeneeskunde; therapeutische specialiteiten op het gebied van oncologie, hematologie en oogheelkunde; en diagnostische beeldvormingsapparatuur en contrastmiddelen, evenals cel- en gentherapie.

Bayer Aktiengesellschaft Samenvatting

Hoe verhouden de winst en inkomsten van Bayer zich tot de beurswaarde?
BAYN fundamentele statistieken
Marktkapitalisatie	€19.45b
Inkomsten(TTM)	-€880.00m
Inkomsten(TTM)	€46.74b

0.4x

P/S-verhouding

-22.1x

Koers/Winstverhouding

Is BAYN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BAYN resultatenrekening (TTM)
Inkomsten	€46.74b
Kosten van inkomsten	€20.03b
Brutowinst	€26.71b
Overige uitgaven	€27.59b
Inkomsten	-€880.00m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Mar 05, 2025

Winst per aandeel (EPS)	-0.90
Brutomarge	57.15%
Nettowinstmarge	-1.88%
Schuld/Eigen Vermogen Verhouding	134.1%

Hoe presteerde BAYN op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.6%

Huidig dividendrendement

-12%

Uitbetalingsratio

BAYN Overzicht aandelen

Beloningen

Risicoanalyse

Bayer Aktiengesellschaft Concurrenten

BUL:THQM

лв1.6b

BUL:SFA

лв928.1m

NYSE:TEVA

US$19.4b

SWX:SDZ

CHF 17.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Third quarter 2024 earnings released: €4.26 loss per share (vs €4.65 loss in 3Q 2023)

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Recent updates

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Third quarter 2024 earnings released: €4.26 loss per share (vs €4.65 loss in 3Q 2023)

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Full year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022)

Dividend of €0.11 announced

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings released: €4.65 loss per share (vs €0.56 profit in 3Q 2022)

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

New major risk - Dividend sustainability

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

First quarter 2023 earnings released: EPS: €2.22 (vs €3.35 in 1Q 2022)

Upcoming dividend of €2.40 per share at 4.0% yield

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Blackford Analysis Ltd.

Bayer AG Announces CEO Changes

Inclusive Capital Partners Provides Information to Shareholders of Bayer Aktiengesellschaft

Union Investment Criticizes Bayer AG Chairman for Lack of Engagement

Bayer Aktiengesellschaft (XTRA:BAYN) agreed to acquire Blackford Analysis Ltd.

Bayer Aktiengesellschaft to Report Q2, 2023 Results on Aug 08, 2023

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Bayer Aktiengesellschaft Samenvatting

0.4x